vs
Prime Medicine, Inc.（PRME）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是Prime Medicine, Inc.的42.4倍（$35.5M vs $838.0K），RECURSION PHARMACEUTICALS, INC.净利率更高（-304.2% vs -5498.7%，领先5194.4%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -61.6%），Prime Medicine, Inc.自由现金流更多（$-37.5M vs $-47.3M）
Prime Medicine, Inc.是一家总部位于美国马萨诸塞州剑桥的生物科技企业，核心业务是依托先导编辑技术开发新型基因治疗方案，致力于为遗传病等相关疾病探索创新治疗手段，推动前沿基因编辑技术的临床转化与应用。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
PRME vs RXRX — 直观对比
营收规模更大
RXRX
是对方的42.4倍
$838.0K
营收增速更快
RXRX
高出743.4%
-61.6%
净利率更高
RXRX
高出5194.4%
-5498.7%
自由现金流更多
PRME
多$9.8M
$-47.3M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $838.0K | $35.5M |
| 净利润 | $-46.1M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | -5800.5% | -304.8% |
| 净利率 | -5498.7% | -304.2% |
| 营收同比 | -61.6% | 681.7% |
| 净利润同比 | -9.0% | 39.6% |
| 每股收益（稀释后） | $-0.22 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRMERXRX
| Q4 25 | $838.0K | $35.5M | ||
| Q3 25 | $1.2M | $5.2M | ||
| Q2 25 | $1.1M | $19.2M | ||
| Q1 25 | $1.5M | $14.7M | ||
| Q4 24 | $2.2M | $4.5M | ||
| Q3 24 | — | $26.1M | ||
| Q2 24 | $0 | $14.4M | ||
| Q1 24 | $591.0K | $13.8M |
净利润PRMERXRX
| Q4 25 | $-46.1M | $-108.1M | ||
| Q3 25 | $-50.6M | $-162.3M | ||
| Q2 25 | $-52.6M | $-171.9M | ||
| Q1 25 | $-51.9M | $-202.5M | ||
| Q4 24 | $-42.3M | $-178.9M | ||
| Q3 24 | — | $-95.8M | ||
| Q2 24 | $-55.3M | $-97.5M | ||
| Q1 24 | $-45.8M | $-91.4M |
毛利率PRMERXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率PRMERXRX
| Q4 25 | -5800.5% | -304.8% | ||
| Q3 25 | -4406.0% | -3327.6% | ||
| Q2 25 | -4787.2% | -916.8% | ||
| Q1 25 | -3603.3% | -1297.9% | ||
| Q4 24 | -2025.7% | -4042.4% | ||
| Q3 24 | — | -377.1% | ||
| Q2 24 | — | -697.4% | ||
| Q1 24 | -8179.5% | -698.4% |
净利率PRMERXRX
| Q4 25 | -5498.7% | -304.2% | ||
| Q3 25 | -4129.1% | -3135.3% | ||
| Q2 25 | -4716.7% | -894.2% | ||
| Q1 25 | -3568.8% | -1373.3% | ||
| Q4 24 | -1936.6% | -3935.5% | ||
| Q3 24 | — | -367.5% | ||
| Q2 24 | — | -676.6% | ||
| Q1 24 | -7743.0% | -662.4% |
每股收益（稀释后）PRMERXRX
| Q4 25 | $-0.22 | $-0.17 | ||
| Q3 25 | $-0.32 | $-0.36 | ||
| Q2 25 | $-0.41 | $-0.41 | ||
| Q1 25 | $-0.40 | $-0.50 | ||
| Q4 24 | $-0.31 | $-0.56 | ||
| Q3 24 | — | $-0.34 | ||
| Q2 24 | $-0.46 | $-0.40 | ||
| Q1 24 | $-0.44 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.0M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $120.9M | $1.1B |
| 总资产 | $342.7M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资PRMERXRX
| Q4 25 | $63.0M | $743.3M | ||
| Q3 25 | $71.4M | $659.8M | ||
| Q2 25 | $53.8M | $525.1M | ||
| Q1 25 | $91.9M | $500.5M | ||
| Q4 24 | $182.5M | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | $55.6M | $474.3M | ||
| Q1 24 | $94.2M | $296.3M |
总债务PRMERXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益PRMERXRX
| Q4 25 | $120.9M | $1.1B | ||
| Q3 25 | $161.8M | $1.0B | ||
| Q2 25 | $60.9M | $919.1M | ||
| Q1 25 | $106.9M | $933.9M | ||
| Q4 24 | $153.1M | $1.0B | ||
| Q3 24 | — | $524.6M | ||
| Q2 24 | $196.6M | $584.4M | ||
| Q1 24 | $243.8M | $401.2M |
总资产PRMERXRX
| Q4 25 | $342.7M | $1.5B | ||
| Q3 25 | $385.0M | $1.4B | ||
| Q2 25 | $279.0M | $1.3B | ||
| Q1 25 | $328.2M | $1.3B | ||
| Q4 24 | $297.5M | $1.4B | ||
| Q3 24 | — | $726.5M | ||
| Q2 24 | $259.7M | $775.9M | ||
| Q1 24 | $311.4M | $557.8M |
负债/权益比PRMERXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.3M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $-37.5M | $-47.3M |
| 自由现金流率自由现金流/营收 | -4480.4% | -133.1% |
| 资本支出强度资本支出/营收 | 34.6% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-167.1M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流PRMERXRX
| Q4 25 | $-37.3M | $-46.1M | ||
| Q3 25 | $-35.0M | $-117.4M | ||
| Q2 25 | $-41.4M | $-76.4M | ||
| Q1 25 | $-48.9M | $-132.0M | ||
| Q4 24 | $16.2M | $-115.4M | ||
| Q3 24 | — | $-59.2M | ||
| Q2 24 | $-45.5M | $-82.2M | ||
| Q1 24 | $-67.7M | $-102.3M |
自由现金流PRMERXRX
| Q4 25 | $-37.5M | $-47.3M | ||
| Q3 25 | $-35.3M | $-117.6M | ||
| Q2 25 | $-43.0M | $-79.6M | ||
| Q1 25 | $-51.3M | $-133.8M | ||
| Q4 24 | $14.5M | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | $-47.4M | $-83.4M | ||
| Q1 24 | $-70.0M | $-109.0M |
自由现金流率PRMERXRX
| Q4 25 | -4480.4% | -133.1% | ||
| Q3 25 | -2880.5% | -2272.5% | ||
| Q2 25 | -3855.1% | -413.9% | ||
| Q1 25 | -3526.8% | -907.4% | ||
| Q4 24 | 662.1% | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% | ||
| Q1 24 | -11849.6% | -789.9% |
资本支出强度PRMERXRX
| Q4 25 | 34.6% | 3.5% | ||
| Q3 25 | 20.2% | 4.7% | ||
| Q2 25 | 141.0% | 16.4% | ||
| Q1 25 | 166.6% | 12.4% | ||
| Q4 24 | 82.0% | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% | ||
| Q1 24 | 393.2% | 48.2% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
